Chapter 10Sins of Omission and Commission

The Missing Accounting Link

On September 20, 2013, the Dutch biotech company Prosensa Holding NV announced that its muscular dystrophy experimental drug Drisapersen failed to help patients more than a placebo. This is the nightmare of every drug and biotech company, and indeed, investors' reaction was swift and harsh: Prosensa's stock plunged 70 percent on the announcement of the trial's failure. It was not a total loss, though, since the stock of Sarepta Therapeutics Inc., a competing biotech firm developing an alternative muscular dystrophy drug increased 18 percent on Prosensa's failure announcement. One company's loss is another's gain. Large drug companies, with diversified portfolios of drugs under development, aren't hit as hard by clinical test failures, but they are hit nevertheless. The large British pharmaceutical company ...

Get The End of Accounting and the Path Forward for Investors and Managers now with the O’Reilly learning platform.

O’Reilly members experience books, live events, courses curated by job role, and more from O’Reilly and nearly 200 top publishers.